-
A national study has found that antiretroviral therapy (ART) drugs are underused among people who seek HIV care from HIV clinics at seven sites across the United States.
-
The Centers for Disease Control and Prevention is issuing $11.6 million in grants to support demonstration projects that implement a combination approach to HIV prevention inclusive of treatment, care, and social services in 12 hard-hit areas across the country.
-
The Food and Drug Administration (FDA) approved changes to the labeling for entecavir (Baraclude®) to provide a dosing regimen for adult patients with chronic hepatitis B (HBV) and decompensated liver disease, based on efficacy data through Week 48 and cumulative safety data from one trial.
-
After a rocky decade, the microbicides field finally is seeing some success, opening up a promising future that should include a wider range of HIV prevention options for women as well as for men who have sex with men (MSM).
-
The HIV community has waited a long time but there might finally be some rewards when the first microbicide options become available worldwide. Among these options are an intravaginal ring that delivers dapivirine and the daily use of tenofovir vaginal gel.
-
Eliminating needlesticks to protect health care workers from HIV and other bloodborne pathogens was once an official federal goal.
-
-
-
Dr. Blackburn is Clinical Assistant Professor in the Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Palo Alto, CA. Dr. Barry is Senior Associate Dean of Global Health, Stanford University School of Medicine, Palo Alto, CA.
-
One month after being treated for "pneumonia," an 8-year-old boy from Botswana presented with a one-day history of fever, cough, and chest pain.
